The RAPID Trial demonstrates the effectiveness of augmentation therapy in slowing emphysema due to Alpha-1 Antitrypsin Deficiency. Results of the trial were announced today at a late-breaking abstract session at the international conference of the American Thoracic Society in Philadelphia. CSL Behring sponsored the trial, which randomly assigned 180 Alpha-1 patients to receive either the augmentation product Zemaira or a placebo for a two-year period.
Disclaimer: The disclaimer provides that such medical information is merely information not advice. If users need medical advice, they should consult a doctor or other appropriate medical professional. The disclaimer also provides that no warranties are given in relation to the medical information supplied on the website, and that no liability will accrue to the website owner or author in the event that a user suffers loss as a result of reliance upon the information.